Sponsor or institution
Clinical trials and research at D3 Bio (Wuxi) Co., Ltd
As of November 12, 2026, Find a Trial lists 5 clinical trials run by D3 Bio (Wuxi) Co., Ltd that are recruiting, at sites in 10 countries (most in Australia (5), South Korea (4), United States (4)). By phase: Phase 1 (3), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 10Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| D3L-002 in Advanced Solid Tumors (Phase 1) | Phase 1 | Macquarie Park and 5 other locations | Recruiting | Jun 25, 2026 |
| Testing D3S-003 alone in people with advanced solid tumors that have a KRAS p.G12D mutation | Phase 1 | New Haven, Connecticut and 8 other locations | Recruiting | Mar 6, 2026 |
| Testing D3L-001 for HER2-Positive Advanced Solid Tumors | Phase 1 | Stanford, California and 8 other locations | Recruiting | Jul 24, 2023 |
| Testing D3S-002 for advanced solid tumors with specific mutations | Phase 1/2 | Detroit, Michigan and 17 other locations | Recruiting | Jun 2, 2023 |
| Treatment for advanced solid tumors with a specific KRAS mutation | Phase 1/2 | Orange, California and 51 other locations | Recruiting | Jun 8, 2022 |
All recruiting trials (5)
-
D3L-002 in Advanced Solid Tumors (Phase 1)
D3L-002 is being tested in adults with advanced solid tumors to see if it is safe, tolerable, and shows any signs of benefit when given in escalating doses.
-
Testing D3S-003 alone in people with advanced solid tumors that have a KRAS p.G12D mutation
This trial will test whether D3S-003 given by itself is safe and shows signs of benefit for people with advanced solid tumors that carry a KRAS p.G12D mutation who have already tried at least one standard therapy.
-
Testing D3L-001 for HER2-Positive Advanced Solid Tumors
This study is testing a new treatment called D3L-001 to see if it is safe and effective for people with advanced HER2-positive solid tumors.
-
Testing D3S-002 for advanced solid tumors with specific mutations
This study is testing a new oral medication called D3S-002 to see if it can help adults with advanced solid tumors that have specific mutations and haven't responded to other treatments.
-
Treatment for advanced solid tumors with a specific KRAS mutation
This study is testing a new oral treatment called D3S-001 for people with advanced solid tumors that have a specific KRAS mutation to see if it works and is safe.
Quick answers
How many clinical trials run by D3 Bio (Wuxi) Co., Ltd are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in Australia (5 trials), South Korea (4 trials), United States (4 trials), China (3 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.